Literature DB >> 19434538

[Expression of glucose transporter 1 in gastric carcinoma and metastatic lymph nodes and its association with prognosis].

Bo Wei1, Lin Chen, Jie Li.   

Abstract

OBJECTIVE: To examine the expression and distribution of glucose transporter 1(GLUT1) in gastric cancer tissues and investigate its relation to clinicopathological parameters and prognosis of patients with gastric carcinoma.
METHODS: Immunohistochemistry was used to examine the expression of GLUT1 in 79 samples of gastric carcinoma tissue. The association of GLUT1 expressive features with clinicopathological characteristics, including histological subtype, depth of invasion, lymph node metastasis, and patients' prognosis were analyzed.
RESULTS: None of normal gastric epithelium expressed GLUT1, whereas 28 of 79 carcinoma samples(35.4%) were positive. Well differentiation type, median differentiation type and poorly differentiation type were GLUT1 positive in 56.5%, 33.3%, and 36.0% cases respectively, while the Signet ring cell carcinoma and mucinous adenocarcinoma were rarely positive(1/6 and 7.7%, respectively). GLUT1 positivity was associated with histological subtype(P=0.044), tumor size(P<0.01), lymph node metastasis(P=0.032), and carcinoma stage(P=0.007). One year survival rates of patients with GLUY1 positive and negative were 64.3% and 90.2% respectively(P=0.035).
CONCLUSION: In human gastric carcinoma, GLUT1 expression is associated with tumor aggressiveness, and may be a useful marker of prognosis.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19434538

Source DB:  PubMed          Journal:  Zhonghua Wei Chang Wai Ke Za Zhi        ISSN: 1671-0274


  6 in total

1.  Glucose transporter 1 (GLUT1) and its emerging role as a significant prognostic marker in systemic malignancies.

Authors:  Shailendra Kapoor
Journal:  Int J Colorectal Dis       Date:  2012-11-14       Impact factor: 2.571

2.  GLUT1 expression in malignant tumors and its use as an immunodiagnostic marker.

Authors:  Kátia C Carvalho; Isabela W Cunha; Rafael M Rocha; Fernanda R Ayala; Mariana M Cajaíba; Maria D Begnami; Rafael S Vilela; Geise R Paiva; Rodrigo G Andrade; Fernando A Soares
Journal:  Clinics (Sao Paulo)       Date:  2011       Impact factor: 2.365

3.  Dual time point [18F]Flurodeoxyglucose (FDG) Positron Emission Tomography (PET)/Computed Tomography (CT) with water gastric distension in differentiation between malignant and benign gastric lesions.

Authors:  Hussein Farghaly; Mohamed Alshareef; Abdullah Alqarni; Mohamed Sayed; Hatem Nasr
Journal:  Eur J Radiol Open       Date:  2020-09-07

4.  Deregulated SLC2A1 Promotes Tumor Cell Proliferation and Metastasis in Gastric Cancer.

Authors:  Shiyan Yan; Yuqin Wang; Meimei Chen; Guangming Li; Jiangao Fan
Journal:  Int J Mol Sci       Date:  2015-07-16       Impact factor: 5.923

Review 5.  Potential Role of Glucose Transporter-1 Expression in Gastric Cancer: A Meta-Analysis and Systematic Review.

Authors:  Jianxin Tao; Ye Zhang; Tong Wang
Journal:  Iran J Public Health       Date:  2020-11       Impact factor: 1.429

6.  Glucose Transporter-1 (GLUT-1) Expression is Associated with Tumor Size and Poor Prognosis in Locally Advanced Gastric Cancer.

Authors:  Chenqing Yin; Bin Gao; Ju Yang; Jingbo Wu
Journal:  Med Sci Monit Basic Res       Date:  2020-03-23
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.